Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation

High-dose therapy with autologous peripheral blood stem cell (PBSC) rescue is widely used for the treatment of malignant disease. CD34 selection of PB SC has been applied as a means of reducing contamination of the graft. Alth ough CD34 selection results in a 2 to 3 log reduction in contaminating tumo r cells without significantly delaying engraftment, many other types of cel ls are depleted from the CD34-enriched grafts and immune reconstitution may be impaired. In the present study, 31 cytomegalovirus (CMV)-seropositive p atients who received myeloablative therapy followed by the infusion of CD34 -selected autologous PBSC were assessed for the development of CMV disease in the first 100 days posttransplant, Seven patients (22.6%) developed CMV disease and 4 patients (12.9%) died from complications of their infection. In a contemporaneous group of 237 CMV-seropositive patients receiving unsel ected, autologous PBSC, only 10 patients (4.2%) developed CMV disease, with 5 deaths (2.1%). In a multivariate logistic regression analysis, the use o f CD34-selected autologous PBSC after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated death s. (C) 1999 by The American Society of Hematology.